Paul P Christopher1, Bradley Anderson2, Michael D Stein3. 1. Department of Psychiatry & Human Behavior, Warren Alpert Medical School, Brown University, Box G-BH, Providence RI 02912 United States. Electronic address: paul_christopher@brown.edu. 2. General Medicine Unit, Butler Hospital, Providence RI United States. 3. Department of Health Law, Policy & Management, School of Public Health, Boston University, United States.
Abstract
INTRODUCTION: Civil commitment is an increasingly used policy intervention to combat the opioid epidemic. Yet little is known about persons who get committed and outcomes following commitment for opioid use. In the current cross-sectional study, we compared the characteristics of persons with and without a history of civil commitment, and the correlates of post-commitment abstinence. METHODS: Between October 2017 and May 2018, we surveyed consecutive persons entering a brief, inpatient opioid detoxification (n = 292) regarding their lifetime experiences with civil commitment for opioid use. RESULTS: Participants averaged 34.6 years of age, 27.1% were female, and 78.1% were White. Seventy-eight (26.7%) experienced civil commitment for opioid use at least once in their lifetime. Committed individuals had significantly higher rates of fentanyl, heroin, and injection drug use, drug overdoses, past incarceration, current criminal justice involvement, and past medication treatment for opioid use (p < .05). The average time to relapse following commitment was 72 days, although 33.8% relapsed on the same day of their release. Longer post-commitment abstinence was significantly associated with post-commitment medication treatment, higher perceived procedural justice (i.e., fairness) during the commitment hearing, positive attitude and higher motivation at the end of commitment, and improvement in attitude during commitment (p < .05). CONCLUSION: Opioid users who experience civil commitment constitute an especially high risk group. A positive commitment experience and post-commitment medication treatment are associated with longer post-commitment abstinence.
INTRODUCTION: Civil commitment is an increasingly used policy intervention to combat the opioid epidemic. Yet little is known about persons who get committed and outcomes following commitment for opioid use. In the current cross-sectional study, we compared the characteristics of persons with and without a history of civil commitment, and the correlates of post-commitment abstinence. METHODS: Between October 2017 and May 2018, we surveyed consecutive persons entering a brief, inpatient opioid detoxification (n = 292) regarding their lifetime experiences with civil commitment for opioid use. RESULTS:Participants averaged 34.6 years of age, 27.1% were female, and 78.1% were White. Seventy-eight (26.7%) experienced civil commitment for opioid use at least once in their lifetime. Committed individuals had significantly higher rates of fentanyl, heroin, and injection drug use, drug overdoses, past incarceration, current criminal justice involvement, and past medication treatment for opioid use (p < .05). The average time to relapse following commitment was 72 days, although 33.8% relapsed on the same day of their release. Longer post-commitment abstinence was significantly associated with post-commitment medication treatment, higher perceived procedural justice (i.e., fairness) during the commitment hearing, positive attitude and higher motivation at the end of commitment, and improvement in attitude during commitment (p < .05). CONCLUSION: Opioid users who experience civil commitment constitute an especially high risk group. A positive commitment experience and post-commitment medication treatment are associated with longer post-commitment abstinence.
Authors: Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin; Bridget F Grant Journal: J Clin Psychiatry Date: 2016-06 Impact factor: 4.384
Authors: Anh T Vo; Christopher Magana; Matthew Hickman; Annick Borquez; Leo Beletsky; Natasha K Martin; Javier A Cepeda Journal: Int J Drug Policy Date: 2021-08-11
Authors: Paul P Christopher; Catherine Stewart; William Manning; Bradley J Anderson; Alexander Woodruff; Jordanna Monteiro; Michael D Stein Journal: J Subst Abuse Treat Date: 2021-05-28
Authors: Pieter Baker; Jaime Arredondo; Annick Borquez; Erika Clairgue; Maria L Mittal; Mario Morales; Teresita Rocha-Jimenez; Richard Garfein; Eyal Oren; Eileen Pitpitan; Steffanie A Strathdee; Leo Beletsky; Javier A Cepeda Journal: Harm Reduct J Date: 2021-07-26
Authors: Olivia K Sugarman; Marcus A Bachhuber; Ashley Wennerstrom; Todd Bruno; Benjamin F Springgate Journal: PLoS One Date: 2020-01-21 Impact factor: 3.240
Authors: Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz Journal: Int J Environ Res Public Health Date: 2020-10-16 Impact factor: 3.390